JP2005504789A5 - - Google Patents

Download PDF

Info

Publication number
JP2005504789A5
JP2005504789A5 JP2003526403A JP2003526403A JP2005504789A5 JP 2005504789 A5 JP2005504789 A5 JP 2005504789A5 JP 2003526403 A JP2003526403 A JP 2003526403A JP 2003526403 A JP2003526403 A JP 2003526403A JP 2005504789 A5 JP2005504789 A5 JP 2005504789A5
Authority
JP
Japan
Prior art keywords
substituted
group
alkyl
unsubstituted
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003526403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005504789A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/027514 external-priority patent/WO2003022274A2/en
Publication of JP2005504789A publication Critical patent/JP2005504789A/ja
Publication of JP2005504789A5 publication Critical patent/JP2005504789A5/ja
Pending legal-status Critical Current

Links

JP2003526403A 2001-09-13 2002-08-28 癌治療のための２−アロイルイミダゾール化合物 Pending JP2005504789A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32210501P 2001-09-13 2001-09-13
PCT/US2002/027514 WO2003022274A2 (en) 2001-09-13 2002-08-28 2-aroylimidazole compounds for treating cancer

Publications (2)

Publication Number Publication Date
JP2005504789A JP2005504789A (ja) 2005-02-17
JP2005504789A5 true JP2005504789A5 (enExample) 2006-01-05

Family

ID=23253436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003526403A Pending JP2005504789A (ja) 2001-09-13 2002-08-28 癌治療のための２−アロイルイミダゾール化合物

Country Status (6)

Country Link
US (2) US6743919B2 (enExample)
EP (1) EP1427413A2 (enExample)
JP (1) JP2005504789A (enExample)
AU (1) AU2002323475B2 (enExample)
CA (1) CA2460345A1 (enExample)
WO (1) WO2003022274A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1427413A2 (en) * 2001-09-13 2004-06-16 Synta Pharmaceuticals Corporation 2-aroylimidazole compounds for treating cancer
CN1915991B (zh) * 2002-02-12 2010-05-26 威斯康星校友研究基金会 用于ah受体作为配体的吲哚噻唑化合物的合成
TW200503738A (en) * 2003-07-16 2005-02-01 Tzu Chi Buddhist General Hospital Method for extracting antineoplastic components from bupleurum scorzonerifolium
EP1697352B1 (en) * 2003-09-24 2012-06-27 Vertex Pharmceuticals Incorporated 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
AU2004285831B2 (en) * 2003-10-31 2011-09-15 Auckland Uniservices Limited Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents
GB0403781D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical compounds
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
EP2269610A3 (en) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
JP2009509128A (ja) * 2005-08-09 2009-03-05 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患の治療
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
CN101360422B (zh) * 2005-11-23 2013-10-23 得克萨斯大学体系董事会 致癌Ras特异性细胞毒化合物及其使用方法
EP1998766A2 (en) * 2005-12-16 2008-12-10 Ironwood Pharmaceuticals, Inc. Useful indole compounds
US7649098B2 (en) * 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
WO2008005908A2 (en) 2006-07-07 2008-01-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
WO2008085302A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
EP2215090B1 (en) * 2007-10-26 2015-03-04 F. Hoffmann-La Roche AG Purine derivatives useful as pi3 kinase inhibitors
US8158624B2 (en) 2008-05-30 2012-04-17 Genetech, Inc. Purine PI3K inhibitor compounds and methods of use
JP2011527342A (ja) * 2008-07-07 2011-10-27 エックスカバリー ホールディング カンパニー エルエルシー Ｐｉ３ｋアイソフォーム選択的阻害剤
SG175708A1 (en) 2009-05-27 2011-12-29 Genentech Inc Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
CN103003279B (zh) 2010-07-14 2015-09-23 弗·哈夫曼-拉罗切有限公司 对PI3K P110δ具有选择性的嘌呤化合物及其使用方法
ES2646834T3 (es) 2010-08-20 2017-12-18 Amira Pharmaceuticals, Inc. Inhibidores de autotaxina y usos de los mismos
AU2011343712B2 (en) 2010-12-16 2015-09-17 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
EP2780010A1 (en) 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CN108841778B (zh) * 2018-04-28 2022-05-17 大连普瑞康生物技术有限公司 一种红豆杉细胞组织培养物
EP4192828A1 (en) 2020-08-04 2023-06-14 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
US11945796B2 (en) 2020-09-16 2024-04-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
TW202313009A (zh) * 2021-07-28 2023-04-01 美商努拉生物科技公司 作為sarm1抑制劑之經取代的吡啶衍生物
WO2023064486A1 (en) * 2021-10-14 2023-04-20 Galileo Biosystems, Inc. Aryl hydrocarbon receptor (ahr) modulators and therapeutic uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272810A3 (en) * 1986-11-26 1988-07-20 Harbor Branch Oceanographic Institution, Inc. Antitumor and antiviral alkaloids
US4866084A (en) * 1987-07-17 1989-09-12 Harbor Branch Oceanographic Institution, Inc. Topsentin compounds effective against viruses and certain tumors
US5290777A (en) * 1993-02-24 1994-03-01 Regents Of The Univ. Of California Use for topsentin compounds and pharmaceutical compositions containing same
NZ321172A (en) * 1995-10-03 2000-02-28 Scripps Research Inst CBI analogs of CC-1065 and the duocarmycins
JP2001503414A (ja) 1996-10-31 2001-03-13 ハーバー ブランチ オーシャノグラフィック インスティテューション インク． 抗神経性炎症化合物および組成物ならびにその使用法
WO1999042092A2 (en) 1998-02-20 1999-08-26 Harbor Branch Oceanographic Institution, Inc. Compounds and methods of use for treatment of neurogenic inflammation
DE69920455T2 (de) 1998-07-08 2005-01-20 Harbor Branch Oceanographic Institution Inc., Fort Pierce Bis-indolederivate und ihre verwendung als entzündungshemmende mittel
SK16482001A3 (sk) * 1999-05-21 2002-04-04 Scios Inc. Indolové deriváty ako inhibítory p38 kinázy
EP1427413A2 (en) * 2001-09-13 2004-06-16 Synta Pharmaceuticals Corporation 2-aroylimidazole compounds for treating cancer

Similar Documents

Publication Publication Date Title
JP2023540228A5 (enExample)
TW536539B (en) Novel substituted imidazole compounds
US20190225633A1 (en) Dna alkylating agents
RU2008136187A (ru) Новое производное кумарина, обладающее противоопухолевой активностью
US8653276B2 (en) 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as urotensin II receptor antagonists
JP2007504160A5 (enExample)
JP2007504284A5 (enExample)
JP2007528417A5 (enExample)
JP2004509113A5 (enExample)
JP2006501181A5 (enExample)
RU2006109108A (ru) Соединения, обладающие активностью антагонистов crth2 рецепторов
BG64507B1 (bg) Производни на карбамида като инхибитори на ензим инозин-5'-монофосфат дехидрогеназа
RU2003133448A (ru) 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс- хемокинового рецептора
JP2007532651A5 (enExample)
RU2012118667A (ru) Гетероциклические соединения, используемые в качестве ингибиторов pdk1
JP2021519776A5 (enExample)
JP2006508970A5 (enExample)
KR20120055571A (ko) 종양성 또는 자가면역 질환 치료용 전구약물로서의 푸라자노벤즈이미다졸
PT1689726E (pt) Derivados de 5-(benz-(z)-ilideno)-tiazolidin-4-ona como agentes imunossupressores
JP2006507355A5 (enExample)
AU2011251622A1 (en) Lipoic acid and nitroxide derivatives and uses thereof
CA2298480A1 (en) Pyridylacrylamide derivatives and nephritis remedies and tgf-.beta. inhibitors containing the same
JP2006508147A5 (enExample)
RU2007118687A (ru) Триазолы, используемые в качестве ингибиторов протеинкиназ
JP2005504795A5 (enExample)